Bob Englert, Steve Crouse
Vortex Biosciences has appointed Bob Englert as its new CEO. Englert, who was previously the firm's chief technology officer, replaces exiting CEO Gene Walther, who has resigned to pursue other interests and will step down both from his position as CEO and as a member of the company's board.
Englert has over 25 years of experience in medical devices and life sciences, with a particular focus on IVD, point of care, and digital health solutions. Before joining Vortex, he served as CEO and founder of Biomedtrics, a diabetes data management company, and prior to that he was COO of Pelikan Technologies. Earlier in his career, Englert also held multiple senior roles at Abbott Laboratories. He holds a BS in biology from the University of Illinois Urbana-Champaign.
Vortex also said that Steve Crouse, who has been the company's chief commercial officer since March 2016, will now assume the position of chief operating officer. Prior to joining Vortex, Crouse served as senior vice president of sales and marketing at Freeslate, a company focused on providing laboratory automation to chemical and pharmaceutical companies.
Bruker announced that it has hired Gerald Herman as its new CFO. He replaces Anthony Mattacchione, whose resignation was announced in February. Herman joined Bruker in 2016 as VP and corporate controller, and has been serving as interim CFO since March 2018. He previously served a corporate VP - Clinical Operations of Parexel International from 2014 to February 2016, and as corporate VP and controller-finance of Parexel from 2008 to 2013. Prior to 2008, he was VP - corporate controller of Presstek.
PetaGene has appointed Michael Hultner as senior vice president and general manager of US operations. Hultner will be responsible for growing the company's commercial operations and client support in the US while contributing to the strategic direction of PetaGene and its products, which include PetaSuite and PetaSuite Cloud Edition for genomic data compression. Hultner joins PetaGene from Seven Bridges, where he was chief strategy officer and general manager of national programs. Prior to that he was chief scientist at Leidos, and he has held several executive positions at Lockheed Martin Health & Life Sciences.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.